Patents Represented by Attorney Nisan A. Steinberg
-
Patent number: 8288351Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 16, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Patent number: 8278280Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 2, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Patent number: 8168592Abstract: Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of treating, preventing or mitigating migraine, are also disclosed.Type: GrantFiled: October 19, 2006Date of Patent: May 1, 2012Assignee: Amgen Inc.Inventors: Colin V. Gegg, Jr., Eileen J. Johnson, Leslie P. Miranda, Kenneth W. Walker, Jerry Ryan Holder, Marie E. Wright, Derin C. D'Amico
-
Patent number: 8043829Abstract: Disclosed is a composition of matter comprising a ShK toxin peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: October 25, 2011Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
-
Patent number: 8008453Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.Type: GrantFiled: August 10, 2006Date of Patent: August 30, 2011Assignee: Amgen Inc.Inventors: Colin V. Gegg, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
-
Patent number: 7910102Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: March 22, 2011Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
-
Patent number: 7906625Abstract: Compositions for treating neurodegenerative or amyloidgenic disorders such as Alzheimer's disease (AD) are provided. More particularly, humanized anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.Type: GrantFiled: January 23, 2006Date of Patent: March 15, 2011Assignee: Amgen Inc.Inventors: Wenyan Shen, Anja L. Biere-Citron
-
Patent number: 7833979Abstract: Disclosed is a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c??(I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector.Type: GrantFiled: April 17, 2006Date of Patent: November 16, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Stefan I. McDonough
-
Patent number: 7834164Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: November 16, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr.
-
Patent number: 7825093Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: November 2, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda
-
Patent number: 7820623Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: October 26, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
-
Patent number: 7803769Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: September 28, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda
-
Patent number: 7750127Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.Type: GrantFiled: August 1, 2008Date of Patent: July 6, 2010Assignee: Amgen Inc.Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
-
Patent number: 7750128Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.Type: GrantFiled: August 1, 2008Date of Patent: July 6, 2010Assignee: Amgen Inc.Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
-
Patent number: 7732399Abstract: The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic acid ester is PentaGalloylGlucose (PGG) and in anther example the gallic acid ester is epigallocatechin gallate (EGCG).Type: GrantFiled: August 30, 2007Date of Patent: June 8, 2010Assignee: Amgen Inc.Inventors: Merrill S. Goldenberg, Jian Hua Gu
-
Patent number: 7662931Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.Type: GrantFiled: August 1, 2008Date of Patent: February 16, 2010Assignee: Amgen Inc.Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
-
Patent number: 7655764Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.Type: GrantFiled: August 1, 2008Date of Patent: February 2, 2010Assignee: Amgen Inc.Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
-
Patent number: 7655765Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.Type: GrantFiled: August 1, 2008Date of Patent: February 2, 2010Assignee: Amgen Inc.Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
-
Patent number: 7645861Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.Type: GrantFiled: August 1, 2008Date of Patent: January 12, 2010Assignee: Amgen Inc.Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
-
Patent number: 7605120Abstract: The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.Type: GrantFiled: October 21, 2004Date of Patent: October 20, 2009Assignee: Amgen Inc.Inventors: Gordon Ng, Benny C. Askew, Jr., Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu